© 2003 European Society of Cardiology
Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM
a Department of Cardiology, University of Hull, Castle Hill Hospital Cottingham, Kingston-upon-Hull HU15 5JQ, UK
b Department of Primary Care and General Practice, University of Birmingham Edgbaston, Birmingham B15 2TT, UK
c Bridlington and District Hospital Bessingby Road, Bridlington YO16 4QP, UK
* Corresponding author. Tel.: +44-1482-624086; fax: +44-1482-624085. E-mail address: a.p.coletta{at}hull.ac.uk
 |
Abstract |
|---|
This article contains a series of reports on recent research developments in the field of heart failure. Reports of key presentations made at the European Society of Cardiology meeting, held in Vienna, Austria, between 30 August and 3 September 2003 are reported. In the CHARM study, candesartan reduced cardiovascular deaths and hospital admissions for heart failure, both in patients who were already taking an ACE-inhibitor and in those who were ACE intolerant. However, results in patients with preserved left ventricular function were less conclusive. The BASEL study supports the use of B-type natriuretic peptide testing to confirm the diagnosis of heart failure in patients presenting with acute dyspnoea. In EUROPA, the largest ever study of secondary prevention of coronary artery disease, long-term treatment with perindopril reduced the incidence of cardiovascular death, myocardial infarction (MI) and cardiac arrest. The ESTEEM study showed that the oral thrombin inhibitor ximelagatran plus aspirin was more effective than aspirin alone in the prophylaxis of major cardiovascular events following MI.
Key Words: CHARM • BASEL • EUROPA • ESTEEM
Received September 4, 2003; Accepted September 12, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G.F. Cleland, A. P. Coletta, and A. L. Clark Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet Eur J Heart Fail, June 1, 2007; 9(6-7): 740 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lechat The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C5 - C12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur. Heart J., June 1, 2005; 26(11): 1115 - 1140. [Full Text] [PDF]
|
|
|
|
 |
|
 K. J.E. Sattler, J. E. Woodrum, O. Galili, M. Olson, S. Samee, F. B. Meyer, X.-Y. Zhu, L. O. Lerman, and A. Lerman Concurrent Treatment With Renin-Angiotensin System Blockers and Acetylsalicylic Acid Reduces Nuclear Factor {kappa}B Activation and C-Reactive Protein Expression in Human Carotid Artery Plaques Stroke, January 1, 2005; 36(1): 14 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Swedberg Conclusions on the management of heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S34 - S36. [Abstract] [PDF]
|
|